Search

Your search keyword '"Young, Barnaby E."' showing total 236 results

Search Constraints

Start Over You searched for: Author "Young, Barnaby E." Remove constraint Author: "Young, Barnaby E."
236 results on '"Young, Barnaby E."'

Search Results

1. Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.

2. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

3. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

4. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial

5. COVID-19 vaccination before or during pregnancy results in high, sustained maternal neutralizing activity to SARS-CoV-2 wild-type and Delta/Omicron variants of concern, particularly following a booster dose or infection

6. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

7. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

8. Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2

9. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

11. SARS-CoV-2 Omicron variant emerged under immune selection

13. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

14. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

16. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

17. Utility of ISARIC 4C Mortality Score, Vaccination History, and Anti-S Antibody Titre in Predicting Risk of Severe COVID-19.

18. Inflammatory risk contributes to post-COVID endothelial dysfunction through anti-ACKR1 autoantibody

19. Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study

22. Employment of a high-throughput functional assay to define the critical factors that influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2.

27. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

28. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial

29. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants

31. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

32. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents:Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)

33. Residual Humoral Immunity Sustained Over Decades in a Cohort of Vaccinia-Vaccinated Individuals.

34. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

35. Sustaining Antimicrobial Stewardship in a High–Antibiotic Resistance Setting

37. Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity

38. Author response for 'Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants'

39. Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical Trial

40. Evaluation of the Safety and Immunogenicity of Different COVID-19 Vaccine Combinations in Healthy Individuals: Study Protocol for a Randomized, Subject-blinded, Controlled Phase 3 Trial [PRIBIVAC]

41. Finger stick blood test to assess postvaccination SARS‐CoV ‐2 neutralizing antibody response against variants

43. Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial

44. Prolonged Inflammation in COVID-19 Survivors Resolves 2 Years After Coronavirus Disease 2019 (COVID-19)

45. Comparison of the Clinical Features, Viral Shedding and Immune Response in Vaccine Breakthrough Infection by the Omicron and Delta Variants

46. Omicron Reactive Multi Protein Specific CD4 T Cells Defines Cellular Immune Response Induced by Inactivated Virus Vaccines

48. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

49. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

50. Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals

Catalog

Books, media, physical & digital resources